Antiplatelets (P2Y12 inhibitors)
- Platelet ADP-receptor blockers
- ACS/PCI + secondary atherothrombosis
- Clopidogrel: common; needs CYP2C19
- Prasugrel: potent; avoid prior stroke/TIA
- Ticagrelor: potent/reversible; dyspnea
- Bleeding is the class-defining toxicity
- Usually paired with aspirin after PCI/ACS
Class at a glance
- Platelet ADP-receptor blockers
Safety / monitoring
- Clopidogrel: common; needs CYP2C19
- Prasugrel: potent; avoid prior stroke/TIA
- Ticagrelor: potent/reversible; dyspnea
Practical pearls
- ACS/PCI + secondary atherothrombosis
- Usually paired with aspirin after PCI/ACS
Safety distinctions
- Bleeding is the class-defining toxicity
Self-check
- What is the main pharmacologic action of Antiplatelets (P2Y12 inhibitors)?
Platelet ADP-receptor blockers.
- What clinically distinguishes Prasugrel within Antiplatelets (P2Y12 inhibitors)?
potent; avoid prior stroke/TIA.
Drugs in this class (5)
All drug classes · Open the interactive console ↗
